Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AZD0780 in Renal Impairment
NCT06592482Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of laropiprant in hypercholesterolemia, dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, Maximum observed plasma concentration and 1 more. Started Aug 2024; status: completed.
02
Drugs
laropiprant
03
Conditions
hypercholesterolemiadyslipidemiaatherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06592482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592482.